Company news

Pacira BioSciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pacira BioSciences Announces Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block

May 25, 2021

Pacira BioSciences to Present at the 2021 Jefferies Virtual Healthcare Conference

May 24, 2021

Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL

May 17, 2021

Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference

May 11, 2021

Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021

May 10, 2021

Pacira BioSciences Reports First Quarter 2021 Financial Results and Business Update

May 3, 2021

Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021

April 20, 2021

Pacira BioSciences Announces Investment in Spine BioPharma

April 19, 2021

Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology

April 13, 2021

Pacira Reports Preliminary Net Product Sales of $118.7 Million for the First Quarter of 2021

April 6, 2021

Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® (bupivacaine liposome injectable suspension) in Pediatric Patients

March 21, 2021

Pacira BioSciences Reports Preliminary Net Product Sales of $36.2 Million for February 2021

March 8, 2021

Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference

March 2, 2021

Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results

February 24, 2021

Pacira to Report 2020 Financial Results on Thursday February 25, 2021

February 17, 2021

Pacira BioSciences Reports Preliminary Net Product Sales of $36.0 Million for January 2021

February 9, 2021

Pacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics

January 25, 2021

Pacira Reports Record Revenue for 2020 of $429.6 Million

January 6, 2021

Pacira BioSciences Reports Preliminary Net Product Sales of $38.9 Million for November 2020

December 8, 2020

Pacira Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain

November 17, 2020

Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020

November 10, 2020

Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update

October 28, 2020

Pacira Launches State-of-the-Art Training Center Dedicated to Advancing Best Practice Regional Approaches to Manage Acute Pain

October 20, 2020

Pacira to Report Third Quarter 2020 Financial Results on Thursday October 29, 2020

October 19, 2020

Pacira BioSciences Reports Preliminary Net Product Sales of $116.9 Million for the Third Quarter of 2020

October 6, 2020

Pacira Receives Positive CHMP Opinion for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain

September 17, 2020

Pacira BioSciences Reports Preliminary Net Product Sales of $36.9 Million for August 2020

September 8, 2020

Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update

August 5, 2020

Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia

August 4, 2020

Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients

August 3, 2020

Pacira to Report Second Quarter 2020 Financial Results on Thursday August 6, 2020

July 29, 2020

Pacira BioSciences Announces Settlement of Government Investigation

July 27, 2020

Pacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025

July 6, 2020

Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes

July 5, 2020

Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes

July 1, 2020

Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update

May 6, 2020

Pacira BioSciences Appoints Donald C. Manning, M.D., Ph.D. as Chief Medical Officer

May 3, 2020

Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020

April 29, 2020

Pacira Reports Record Fourth Quarter and Full-Year Revenues

February 19, 2020

Pacira to Report 2019 Financial Results on Thursday February 20, 2020

February 12, 2020

Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services

January 20, 2020

Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million

January 8, 2020

EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients

January 6, 2020

Pacira BioSciences Announces Positive Results from Phase 3 PLAY Study of EXPAREL® in Pediatric Patients

December 16, 2019

Pacira BioSciences Reports Third Quarter 2019 Financial Results and Business Update

November 6, 2019

Pacira to Report Third Quarter 2019 Financial Results on Thursday November 7, 2019

October 24, 2019

Pacira BioSciences Set to Join S&P SmallCap 600

September 23, 2019

Pacira BioSciences Appoints Chris Christie to Board of Directors

September 18, 2019

Pacira BioSciences Completes Enrollment in Multicenter Registration Study of EXPAREL® in Pediatric Patients

September 16, 2019

← Newer news releases

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.